HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

Benzinga · 1d ago
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.